Clinical Trial Update: A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TQB2450 injection in PD-L1 positive recurrent or metastatic cervical cancer (clinical trial update).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Recurrent or Metastatic Cervical Cancer | Phase 2 | Status: UNKNOWN